Who Paid My Doc
Sheldon Litwin
Advanced Heart Failure and Transplant Cardiology Charleston, SC Medical Doctor
NPI 1861447989 CMS profile 84557
171 Ashley Ave, Charleston, SC 29425
General payments
$86,264
Research payments
$62,869
Ownership & investment interest
$0
Research they led as principal investigator
$1,000,426
Through program year 2025, Sheldon Litwin of Charleston, SC is reported in the CMS Open Payments database as having received $86,264 across 48 general payments and $62,869 in research payments paid to them. Separately, studies naming them as principal investigator received $1,000,426 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 90th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $14,325 | 5 | |
| 2024 | General | $13,706 | 7 | |
| 2024 | Research | $33,599 | 1 | |
| 2023 | General | $14,225 | 7 | |
| 2023 | Research | $6,300 | 1 | |
| 2022 | General | $13,907 | 22 | |
| 2021 | General | $10,150 | 3 | |
| 2021 | Research | $22,970 | 2 | |
| 2020 | General | $5,600 | 1 | |
| 2019 | General | $14,350 | 3 |
Beside peers
- Sheldon Litwin
- Advanced Heart Failure and Transplant Cardiology median
- Middle half of Advanced Heart Failure and Transplant Cardiology
- National median
In program year 2025, general payments to Sheldon Litwin were reported at $14,325. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.
Show as a table
| Year | Sheldon Litwin | Advanced Heart Failure and Transplant Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $14,350 | $863 | $224–$4,562 | $163 |
| 2020 | $5,600 | $452 | $122–$3,992 | $114 |
| 2021 | $10,150 | $550 | $159–$3,571 | $132 |
| 2022 | $13,907 | $729 | $221–$4,357 | $149 |
| 2023 | $14,225 | $1,002 | $309–$5,827 | $160 |
| 2024 | $13,706 | $931 | $273–$5,204 | $164 |
| 2025 | $14,325 | $1,024 | $289–$6,890 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 34 drugsPart D claims
1,480
Drug cost
$486,227
Branded share of claims
35.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 162 | $148,621 | |
| Eliquis Apixaban | Brand | 61 | $52,298 | |
| Mounjaro Tirzepatide | Brand | 43 | $49,625 | |
| Farxiga Dapagliflozin Propanediol | Brand | 59 | $46,613 | |
| Repatha Sureclick Evolocumab | Brand | 25 | $40,054 | |
| Wegovy Semaglutide | Brand | 25 | $39,849 | |
| Xarelto Rivaroxaban | Brand | 31 | $30,667 | |
| Ozempic Semaglutide | Brand | 29 | $29,338 | |
| Entresto Sacubitril/Valsartan | Brand | 24 | $28,635 | |
| Icosapent Ethyl | Generic | 13 | $4,725 |
The 10 drugs with the highest cost, of 34 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 21 billing codesPaid by Medicare
$68,758
Medicare patients
826
Services billed
1,647
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Heart failure | 63% | |
| Ischemic heart disease | 55% | |
| Arthritis | 55% | |
| Atrial fibrillation | 51% | |
| Chronic kidney disease | 44% | |
| Diabetes | 41% | |
| COPD | 28% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
52 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Advanced Heart Failure and Transplant Cardiology in South Carolina
Patrick McCann
Advanced Heart Failure and Transplant Cardiology · Columbia, SC
Ryan Tedford
Advanced Heart Failure and Transplant Cardiology · Charleston, SC
Michael Zile
Advanced Heart Failure and Transplant Cardiology · Charleston, SC
Anil Purohit
Advanced Heart Failure and Transplant Cardiology · West Columbia, SC
James Ampadu
Advanced Heart Failure and Transplant Cardiology · Columbia, SC
Daniel Judge
Advanced Heart Failure and Transplant Cardiology · Charleston, SC
Related records
Advanced Heart Failure and Transplant Cardiology in South Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Advanced Heart Failure and Transplant Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in South Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.